Thursday, May 30, 2019

Insilico Medicine to present at the CogX Festival of AI and Emerging Technology

Thursday, May 30, 2019 - Insilico Medicine, a biotech company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI for drug discovery and productive longevity at the CogX Festival of AI and Emerging Technology in London, on June 10th. 
The CogX Festival of AI and Emerging Technologybrings together more than 100 most innovative, disruptive tech startups in the world, as well as the brightest and most influential AI and emerging technology leaders to understand and experience the technology landscape trends and get the latest governmental and academic opinions on the opportunities and challenges for applications of AI and emerging technology. The CogX Festival provides an ideal platform for partnering, establishing and strengthening relationships and ecosystems with AI and emerging technology leaders from across the globe.
"We are on the brink of a technological revolution in healthcare where data collected from all different sources will influence the way we cure diseases. This approach aims to master disease treatment and extend it's branches into preventive and longevity based means. At Insilico, we are using AI as a powerful tool to identify targets for drug development, and with the ability to simulate and accelerate research processes, artificial intelligence helps more drugs to be discovered. We are thrilled to be able to share the results of our research at the CogX - an incredible artificial intelligence festival coming to London this June," said Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine.
"I am really fascinated by the opportunity to participate in the CogX Festival, the event that contributes to the development of the innovative technology industries. It is such a great chance to listen to, learn from, and engage in debates with the brightest minds from the industry, and academia, and I am looking forward to sharing my own perspective as a female researcher and a deep learning scientist," said Polina Mamoshina, Senior Research Scientist at Insilico Medicine.
###
For further information, images or interviews, please contact:
Contact: Klug Gehilfe ai@pharma.ai
Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontologydemonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine. Insilico published an overview of its results in aging research including the development of AI aging biomarkers, target identification, cross-species comparison and geroprotector discovery in Aging Research Reviews, one of the highest-impact journals in the field.
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.
Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8.

Posted by at No comments:

Tuesday, May 28, 2019

Vadim Gladyshev to present at the 6th Aging Research for Drug Discovery Forum in Basel

Vadim Gladyshev, Ph.D., Professor of Medicine at Brigham and Women's Hospital, Harvard Medical School, to present at the 6th Aging Research for Drug Discovery Forum in Basel, Switzerland

Thursday, May 23, 2019 - Today Insilico Medicine, a biotechnology company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, and the Scheibye-Knudsen Lab, University of Copenhagen, announce the presentation of Vadim Gladyshev, Ph.D., Professor of Medicine at Brigham and Women's Hospital, Harvard Medical School, at the 6th Aging Research, Drug Discovery, and AI Forum during the Basel Life Congress, September 10-12, 2019, Basel, Switzerland.
The rate of aging varies significantly across species and cell types and is further modified by genetic and environmental factors. This diversity sheds light on general principles and mechanisms of lifespan control, and they can be studied by applying comparative genomics approaches to short- and long-lived species and carrying out analyses across panels of mammals. 
The scientists at the Dr. Gladyshev's lab sequenced the genomes of several mammals with exceptional lifespan and identified genes that may contribute to their longevity. They also carried out analyses of gene expression, metabolites and elements across large panels of mammals. 
The presentation will focus on the results of these studies, pointing to both lineage-specific and common adaptations to longevity and identifying signatures, that characterize species lifespan and the effects of interventions that adjust lifespan within species. Using these signatures, one may identify new pharmacological, dietary and genetic interventions with the potential to increase lifespan. To characterize longevity interventions in mice, blood and multi-tissue DNA methylation clocks were developed as well. Together, these genomics approaches and tools offer a platform for unbiased discovery and validation of longevity interventions in mammals. 
"There will be an immediate and broad impact in the field, if an intervention is proven to extend human lifespan. Studies on model organisms can guide us in finding the best ways to extend human lifespan," said Vadim Gladyshev, Professor of Medicine at Brigham and Women's Hospital, Harvard Medical School.
"It is a great pleasure that Professor Vadim Gladyshev is joining us in Basel. Professor Gladyshev is at the forefront of redox biology and aging, two fields that are merging in the context of healthy longevity. Recently, he has pioneered cross species investigations into aging allowing us to identify new potential targets for healthy aging. I am therefore extremely grateful that Professor Gladyshev will visit us in Basel, " said Morten Scheibye-Knudsen, MD, Ph.D., University of Copenhagen.
"Over the last 5 years, the "Aging & Drug Discovery" and "AI for Healthcare" forums have been leading events at BaselLife, attracting hundreds of delegates from over 50 countries. This year, we are combining the 2 platforms into a 3 day-event titled "the 6th Aging, AI and Drug Discovery Forum" to explore the convergence of these 2 cutting edge disciplines. Under the program leadership of Professor Morten Scheibye-Knudsen and Dr. Alex Zhavoronkov, with distinguished scientists and industry experts in the field, we look forward to exploring breakthroughs for this great healthcare need for the planet," said Dr. Bhupinder Bhullar, Chair, Innovation Forum program committee, Basel Life 2019. 
"The 6th annual Aging Research, Drug Discovery, and AI Forum at Basel Life will have a fresh program featuring some of the most prominent scientists and industry players in aging and longevity research covering the theory, applications and convergence of these three exciting areas," said Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine, Inc.
The 6th Aging Research for Drug Discovery Forum Basel will bring together leaders in the aging, longevity, and drug discovery field, to describe the latest progress in the molecular, cellular and organismal basis of aging and the search for interventions. Furthermore, the forum will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. This event intends to bridge academic and commercial research and foster collaborations that will result in practical solutions to one of humanity's most challenging problems: aging. The Forum will be held in Basel, Switzerland, September 10-12, 2019. 
###
For further information, images or interviews, please contact:
Ola Popova ola@pharma.ai
About Vadim Gladyshev
Vadim Gladyshev is a Professor of Medicine at Brigham and Women's Hospital, Harvard Medical School, Director of the Center for Redox Medicine, and Associate Member of the Broad Institute. He obtained all his degrees from Moscow State University, followed by postdoc training at the National Institutes of Health and a first faculty position at the University of Nebraska. He seeks to understand the nature of aging and to define the principles of lifespan control. His lab applies high-throughput and computational approaches to achieve systems level understanding of the aging process and develop interventions that extend lifespan.
About Brigham and Women's Hospital
Boston's Brigham and Women's Hospital (BWH) is an international leader in virtually every area of medicine and has been the site of pioneering breakthroughs that have improved lives around the world. A major teaching hospital of Harvard Medical School, BWH has a legacy of excellence that continues to grow year after year. BWH includes 150 outpatient practices with over 1,200 physicians. We serve patients from New England, throughout the United States, and from 120 countries around the world.
BWH is an internationally-known referral center for the most complex cases in nearly all areas of medicine. In fact, U.S. News and World Report has consistently ranked us a top hospital and among the best in specialty areas including cancer, cardiology and heart surgery, gynecology, neurology and neurosurgery, orthopedics, and rheumatology.
About Harvard Medical School 
Since the School was established in 1782, faculty members have improved human health by innovating in their roles as physicians, mentors and scholars. They've piloted educational models, developed new curricula to address emerging needs in health care, and produced thousands of leaders and compassionate caregivers who are shaping the fields of science and medicine throughout the world with their expertise and passion. The mission of the school is to nurture a diverse, inclusive community dedicated to alleviating suffering and improving health and well-being for all through excellence in teaching and learning, discovery and scholarship, and service and leadership. 
Official website: https://hms.harvard.edu/
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8. 
Official website: http://insilico.com
About the Scheibye-Knudsen Laboratory
The growing proportion of the elderly population represents an increasing socioeconomic challenge, not least because of age-associated diseases. It is therefore increasingly pertinent to find interventions for age-associated diseases such as Alzheimer's, Parkinson's and cardiovascular diseases. Although the cause of aging is currently unknown accumulation of damage to our genome, the DNA, may be a contributing factor.
In the Scheibye-Knudsen lab we try to understand the cellular and organismal consequences of DNA damage with the aim of developing interventions. We have discovered that DNA damage leads to changes in certain metabolites and that replenishment of these molecules may alter the rate of aging in model organisms. These findings suggest that normal aging and age-associated diseases may be malleable to similar interventions. The hope is to develop interventions that will allow everyone to live healthier, happier and more productive lives.
Laboratory website: http://scheibye-knudsen.com/
About the University of Copenhagen
With over 40,000 students and more than 9,000 employees, the University of Copenhagen is the largest institution of research and education in Denmark and among the highest ranked universities in Europe. The purpose of the University - to quote the University Statute - is to 'conduct research and provide further education to the highest academic level'. Approximately one hundred different institutes, departments, laboratories, centres, museums, etc., form the nucleus of the University.
About Basel Life 2019 
Aging Research for Drug Discovery Forum description
In this symposium, leaders in the aging, longevity, and drug discovery field will describe the latest progress in the molecular, cellular and organismal basis of aging and the search for interventions. Furthermore, the forum will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. This event intends to bridge academic and commercial research and foster collaborations that will result in practical solutions to one of humanity's most challenging problems: aging. A panel of thought-leaders will give us their cutting edge reports on the latest progress in our quest to extend the healthy lifespan of everyone on the planet. 
Conference Official Website: https://www.basellife.org/2019.html
Posted by at No comments:

Monday, May 27, 2019

Insilico to present at the 2019 Innovative China Conference

Insilico to present its research at the Bank of America Merrill Lynch's 4th Innovative China Conference
Friday, May 24, 2019 - Insilico Medicine, a biotech company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI for drug discovery and productive longevity at the Bank of America Merrill Lynch's 4th 2019 Innovative China Conference on May 27, in Shenzhen. 
Artificial intelligence (AI) has the potential to transform the pharmaceutical industry, making the hunt for new pharmaceuticals quicker and more effective. With AI comes the potential to improve drug approval rates, reduce development costs, and help patients comply with their treatments. 
At Insilico, AI has been used as a powerful tool to identify targets for drug development, and with the ability to simulate and accelerate research processes, artificial intelligence helps more drugs to be discovered and come to market quickly. The presentation will focus on the latest advances in artificial intelligence for discovery, development and real world evidence collection of drugs and geroprotectors.
"We are happy to present our latest research at the 2019 Innovative China Conference, which gathers the leading industry leaders. The topic of artificial intelligence for drug discovery is rapidly gaining popularity, and we are happy to be at the leading edge of this research and one of the innovation drivers in the area," said Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine, Inc.
China is transitioning into a more consumption-driven, service-led economy, powered by dynamic companies focused on innovation. Bank of America Merrill Lynch's 4th Innovative China Conference in Shenzhen, with over 100 leading China innovative companies participating, will give an insight into the future of life sciences industry in China. The conference is three full days of keynote presentations and thematic panel discussions with policy makers, thought leaders, industry experts, C-level corporate executives to present on innovative themes and other topical ideas.
###
For further information, images or interviews, please contact: 
Contact: Klug Gehilfe 
ai@pharma.ai 
Website: http://insilico.com/
Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine. Insilico published an overview of its results in aging researchincluding the development of AI aging biomarkers, target identification, cross-species comparison and geroprotector discovery in Aging Research Reviews, one of the highest-impact journals in the field.
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.
Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8.
Posted by at No comments:

Thursday, May 23, 2019

Insilico and Ageing research at King's partner for health-span and longevity collaboration

Insilico and Ageing Research at King's enter a research collaboration to optimize opportunities for healthy ageing and longevity
Wednesday, May 22 - Insilico Medicine, a biotech company developing the end-to-end drug discovery pipeline utilizing next-generation artificial intelligence, announces its partnership with Ageing Research at King's (ARK) - dedicated to enhancing multidisciplinary research collaborations across King's College London and King's Health Partners to better understand the mechanisms of ageing and improving health-span. The goal of this collaboration is to employ a set of AI-based methods, to explore patterns that have significant potential to impact healthy ageing, age-related diseases and targeted therapeutics.

ARK is uniquely positioned to address the challenges of an ageing world, and to provide answers at multiple levels, from cellular mechanisms to social sciences. ARK will develop a programme of events to facilitate networking in AI research across King's and to foster research supported by UK Research and Innovation, charities and industrial partners both in the UK and globally. The ARK partnership with Insilico provides an opportunity to deliver academic excellence in AI methods for ageing and longevity research. This will complement the recently launched London Medical Imaging and AI Centre for Value Based Health Care at King's.
"The applications of modern artificial intelligence algorithms within the field of aging research offer tremendous opportunities. Insilico Medicine is one of the first AI companies to combine the expertise in artificial intelligence applied to the cutting-edge medicinal chemistry and target identification, and I am certain that our set of software tools, deep domain expertise in target identification and medicinal chemistry, and focus on aging and age-related diseases will contribute to the ARK's initiative and research." - said Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine, Inc.
"ARK is committed to bringing together AI expertise across King's to explore its utility and impact for healthy ageing. With larger multifactorial repositories of data in ageing research; incorporation of advanced AI methods represents an opportunity to develop novel therapeutic approaches in precision medicine for age-related diseases and to identify strategies for healthy ageing. We are delighted to partner with Insilico Medicine to bring together industry leading AI experts with ARK-associated academics and clinicians, to accelerate ageing and longevity research." said Richard Siow, Ph.D., Director of ARK and former Vice-Dean (International), Faculty of Life Sciences & Medicine, King's College London.
###
For further information, images or interviews, please contact:
Insilico Medicine: Klug Gehilfe ai@pharma.ai
Ageing Research at King's: Chris Albertyn chris.albertyn@kcl.ac.uk
About Ageing Research at King's (ARK) 
ARK is a cross-faculty multidisciplinary consortium of academics and clinicians which brings together scholarship and research in ageing in several complementary areas. ARK represents King's world class excellence for research on the biology of ageing, from the basic mechanisms in biogerontology to clinical translation and the social impact of ageing. The primary purpose of ARK is to enhance multidisciplinary research collaborations across King's College London and King's Health Partners Academic Health Sciences Centre to better understand the mechanisms of ageing and improving health-span. As ageing consists of complex systems at the level of biomedicine, psychology and society, ARK fosters a multidisciplinary approach to better understand the processes involved in ageing and longevity. 
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered in Hong Kong, with R&D sites and management resources in the US, Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in artificial intelligence for biomarker discovery, target identification, generation of novel chemistry and aging research.
Since 2015 Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. 
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8.

Posted by at No comments:

Tuesday, May 21, 2019

Insilico to present at the 2019 Africa Health Conference

Tuesday, May 21, 2019 - Insilico Medicine, a biotech company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI at the 2019 Africa Health: Digital Health Conference on May 28. 
The increased availability of data and recent advancements in Artificial Intelligence (AI) present the unprecedented opportunities in healthcare and major challenges for the patients, developers, providers and regulators.
Benefiting from the increasing availability of useful data, advancements in AI help to reduce costs of drug discovery, bringing vital drugs faster to the market. There are many regions where these transformations are needed, including Africa, where approximately 70% of all pharmaceuticals are imported from other countries, which has not been quite sustainable. 
Artificial intelligence techniques help to make great contribution to the pharma industry in Africa, as well as tackle more local health challenges while creating more employment opportunities for the many scientists who could be employed to work towards better and more affordable healthcare solutions for all.
The presentation will cover the latest advances in artificial intelligence and blockchain technologies that accelerate the biomedical research and enable patients to control and benefit from their medical data, that might serve as an incentive to undergo constant health monitoring in Africa.
"We are happy to present our latest research at the 2019 Africa Health Conference, which gathers the leading industry leaders. The topic of artificial intelligence in healthcare is extremely important for the countries located in Africa, and we are happy to be at the leading edge of this research and one of the innovation drivers in the area," said Iraneus Ogu, Africa AI, Blockchain and Longevity Consultant at Insilico Medicine.
Africa Health is the largest gathering of healthcare companies, technology, products and services in the continent. Taking place from 28 - 30 of May 2019, the event is expected to welcome more than 560 exhibiting companies and 10,500 attendees from more than 40 countries.
###
For further information, images or interviews, please contact:
Contact: Klug Gehilfe
Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontologydemonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine. Insilico published an overview of its results in aging research including the development of AI aging biomarkers, target identification, cross-species comparison and geroprotector discovery in Aging Research Reviews, one of the highest-impact journals in the field.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8.
Posted by at 1 comment:

Thursday, May 16, 2019

Insilico to present at the 2019 DIA China Annual Meeting

Wednesday, May 15, 2019 - Insilico Medicine, a biotech company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI for drug discovery and productive longevity at 2019 DIA China Annual Meeting in Beijing on May 23. 
Artificial intelligence (AI) has the potential to transform the pharmaceutical industry, making the hunt for new pharmaceuticals quicker and more effective. With AI comes the potential to improve drug approval rates, reduce development costs, and help patients comply with their treatments.
The 2019 DIA China Annual Meeting from May 20 - 23 (ICH Day on May 20) is the largest, event in the life sciences industry designed to foster the international exchange of actionable insights to improve health globally through the advancement of lifesaving medicines and technologies in the Asia Pacific region. The event will bring together 2000+ pharmaceutical R&D professionals from different continents and regions, involved at all levels of the health care product development spectrum, to discuss recent and upcoming transformational changes for China's innovation and regulatory environments.
At Insilico, AI has been used as a powerful tool to identify targets for drug development, and with the ability to simulate and accelerate research processes, artificial intelligence helps more drugs to be discovered and come to market quickly. The presentation will focus on the latest advances in artificial intelligence for discovery, development and real world evidence collection of drugs and geroprotectors.
"We are happy to present our latest research at the 2019 DIA China Annual Meeting, which gathers the leading longevity leaders. The topic of artificial intelligence for drug discovery is rapidly gaining popularity, and we are happy to be at the leading edge of this research and one of the innovation drivers in the area," said Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine, Inc.
###
For further information, images or interviews, please contact:
Contact: Klug Gehilfe ai@pharma.ai Website: http://insilico.com/
Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontologydemonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine. Insilico published an overview of its results in aging research including the development of AI aging biomarkers, target identification, cross-species comparison and geroprotector discovery in Aging Research Reviews, one of the highest-impact journals in the field.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8.
Posted by at No comments:

Wednesday, May 8, 2019

Insilico to present at the Russian Pharmaceutical Forum

Wednesday, May 8, 2019 - Insilico Medicine, a biotech company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI for drug discovery and productive longevity at the Russian Pharmaceutical Forum in Saint Petersburg, May 15. 

Artificial intelligence (AI) has the potential to transform the pharmaceutical industry, making the hunt for new pharmaceuticals quicker and more effective. With AI comes the potential to improve drug approval rates, reduce development costs, and help patients comply with their treatments. 
At Insilico, AI has been used as a powerful tool to identify targets for drug development, and with the ability to simulate and accelerate research processes, artificial intelligence helps more drugs to be discovered and come to market quickly. The presentation will focus on the latest advances in artificial intelligence for drug discovery, conducting clinical trials, personalised medicine, and rare disease identification.
"We are happy to present our latest research at the Russian Pharmaceutical Forum, which gathers the leading industry leaders. The topic of artificial intelligence for drug discovery is rapidly gaining popularity, and we are happy to be at the leading edge of this research and one of the innovation drivers in the area," said Alex Aliper, President of EMEA at Insilico Medicine.
The Russian Pharmaceutical Forum remains the largest independent international conference in Russia devoted to addressing the pharmaceutical industry's most pressing issues. The key topics the Forum aims to approach, include: digitalisation in healthcare and pharmaceutical sector, pharmaceutical drug reimbursement, drug labeling, the patient-centric model, state purchasing, import substitution, innovation potential. 
###
For further information, images or interviews, please contact:
Contact: Klug Gehilfe
Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontologydemonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine. Insilico published an overview of its results in aging research including the development of AI aging biomarkers, target identification, cross-species comparison and geroprotector discovery in Aging Research Reviews, one of the highest-impact journals in the field.

About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.
Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8.
Posted by at No comments:
Subscribe to: Posts (Atom)